BhutanTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.072 (0.039–0.12) 9.5 (5.1–15)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.13 (0.04–0.29)
Prevalence  (includes HIV+TB) 1.5 (0.57–2.7) 190 (75–359)
Incidence  (includes HIV+TB) 1.3 (1.1–1.4) 164 (148–181)
Incidence (HIV+TB only) 0.091 (0.072–0.11) 12 (9.4–15)
         
Case detection, all forms (%) 85 (77–94)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.9–2.6) 35 (21–52)
MDR-TB cases among notified pulmonary
TB cases
12 (10–14) 25 (15–37)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 454   55
Pulmonary, clinically diagnosed 91   0
Extrapulmonary 466   0
       
Total new and relapse 1 066    
Previously treated, excluding relapses 16    
Total cases notified 1 082    
Among 1 066 new and relapse cases:
56 (5%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 380 (84%) 44 (62%) 431
Laboratory-confirmed RR-/MDR-TB cases     61
Patients started on MDR-TB treatment ***     122
TB/HIV 2014 Number (%)
TB patients with known HIV status 703 (65)
HIV-positive TB patients 7 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 7 (100)
HIV-positive people screened for TB 251  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (91) 1 080
Previously treated cases, excluding relapse, registered in 2013 (60) 35
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (100) 10
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 4.2
Culture (per 5 million population) 6.5
Drug susceptibility testing (per 5 million population) 6.5
Sites performing Xpert MTB/RIF  
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-30 Data: www.who.int/tb/data